Jubira Gold 20 Capsule is a combination pharmaceutical formulation containing Aspirin (75 mg), Rosuvastatin (20 mg), and Clopidogrel (75 mg), designed for the management of cardiovascular conditions. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby reducing thromboxane A2 production and preventing platelet aggregation. Rosuvastatin, a potent HMG-CoA reductase inhibitor, effectively lowers low-density lipoprotein cholesterol (LDL-C) levels and exerts pleiotropic effects including anti-inflammatory and plaque-stabilizing properties. Clopidogrel, another antiplatelet agent, selectively inhibits the ADP P2Y12 receptor on platelet surfaces, further reducing platelet activation and aggregation. The combined use of these agents in Jubira Gold 20 Capsule is indicated for secondary prevention of atherosclerotic cardiovascular disease, including myocardial infarction, stroke, and peripheral arterial disease, particularly in patients at high risk for thrombotic events. This combination therapy aims to reduce the incidence of cardiovascular morbidity and mortality by addressing multiple pathogenic pathways. Caution is advised in patients with bleeding disorders, hepatic impairment, or hypersensitivity to any component. Monitoring for adverse effects such as bleeding, myopathy, or gastrointestinal irritation is recommended during therapy. Jubira Gold 20 Capsule should be used under strict medical supervision to optimize therapeutic outcomes.